BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 33439058)

  • 1. Arsenic trioxide and all-trans retinoic acid in the treatment of children with newly diagnosed acute promyelocytic leukemia.
    Li SY; Lu Y; Liu HC; Gang EJ; Le J; Qian SY; Tang SH; Si T; Pei RZ
    Leuk Lymphoma; 2021 May; 62(5):1267-1270. PubMed ID: 33439058
    [No Abstract]   [Full Text] [Related]  

  • 2. Fertility and parenthood in patients with acute promyelocytic leukemia treated with Arsenic Trioxide and All-Trans retinoic acid.
    Singh C; Saini M; Jain A; Lad D; Prakash G; Khadwal A; Naseem S; Malhotra P
    Blood Cancer J; 2024 Jan; 14(1):14. PubMed ID: 38238308
    [No Abstract]   [Full Text] [Related]  

  • 3. Variant acute promyelocytic leukaemia with novel NAB2::RARA fusion shows clinical all-trans retinoic acid and arsenic trioxide sensitivity.
    Ng Liet Hing M; Ryland GL; Nguyen T; Tiong IS; Dun K; Ninkovic S; Nedumannil R; Westerman DA; Blombery PA; Chan KL; Bajel A
    Br J Haematol; 2023 Aug; 202(4):893-896. PubMed ID: 37280781
    [No Abstract]   [Full Text] [Related]  

  • 4. Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial.
    Burnett AK; Russell NH; Hills RK; Bowen D; Kell J; Knapper S; Morgan YG; Lok J; Grech A; Jones G; Khwaja A; Friis L; McMullin MF; Hunter A; Clark RE; Grimwade D;
    Lancet Oncol; 2015 Oct; 16(13):1295-305. PubMed ID: 26384238
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Arsenic and apoptosis in the treatment of acute promyelocytic leukemia.
    Look AT
    J Natl Cancer Inst; 1998 Jan; 90(2):86-8. PubMed ID: 9450562
    [No Abstract]   [Full Text] [Related]  

  • 6. Combination brings long-term remission in acute promyelocytic leukemia refractory for both all-trans retinoic acid and arsenic trioxide.
    Sasaki M; Sugimoto K; Isobe Y; Oshimi K
    Eur J Haematol; 2008 Aug; 81(2):160. PubMed ID: 18363868
    [No Abstract]   [Full Text] [Related]  

  • 7. Efficacy of prolonged therapy with combined arsenic trioxide and ATRA for relapse of acute promyelocytic leukemia.
    Breccia M; Cicconi L; Minotti C; Latagliata R; Giannì L; Lo-Coco F
    Haematologica; 2011 Sep; 96(9):1390-1. PubMed ID: 21659361
    [No Abstract]   [Full Text] [Related]  

  • 8. All-trans-retinoic acid and arsenic trioxide as initial therapy for acute promyelocytic leukemia.
    Quezada G; Kopp L; Estey E; Wells RJ
    Pediatr Blood Cancer; 2008 Jul; 51(1):133-5. PubMed ID: 18293388
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Therapies for newly diagnosed acute promyelocytic leukemia].
    Yokoyama Y
    Rinsho Ketsueki; 2020; 61(9):1166-1173. PubMed ID: 33162512
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ATRA plus arsenic gets another "A" in APL.
    Park JH
    Blood; 2012 Aug; 120(8):1535-6. PubMed ID: 22918418
    [TBL] [Abstract][Full Text] [Related]  

  • 11. What is the standard regimen for patients with acute promyelocytic leukemia?
    Lo-Coco F; Cicconi L
    Curr Hematol Malig Rep; 2014 Jun; 9(2):138-43. PubMed ID: 24729066
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Higher than normal mitochondrial DNA content associated with better outcome in acute promyelocytic leukaemia? Maybe.
    Wiernik PH
    Br J Haematol; 2023 Jan; 200(2):126-127. PubMed ID: 36342482
    [TBL] [Abstract][Full Text] [Related]  

  • 13. How I treat acute promyelocytic leukemia.
    Tallman MS; Altman JK
    Blood; 2009 Dec; 114(25):5126-35. PubMed ID: 19797519
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treating low- and intermediate-risk acute promyelocytic leukemia with and without chemotherapy: A comparison in a tertiary care center.
    Saxena M; Madabhavi IV; Patel A; Panchal H; Anand A
    J Cancer Res Ther; 2023; 19(5):1371-1378. PubMed ID: 37787311
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Addition of Arsenic Trioxide into Induction Regimens Could Not Accelerate Recovery of Abnormality of Coagulation and Fibrinolysis in Patients with Acute Promyelocytic Leukemia.
    Zhang Y; Wu S; Luo D; Zhou J; Li D
    PLoS One; 2016; 11(1):e0147545. PubMed ID: 26812490
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia.
    Lo-Coco F; Avvisati G; Vignetti M; Thiede C; Orlando SM; Iacobelli S; Ferrara F; Fazi P; Cicconi L; Di Bona E; Specchia G; Sica S; Divona M; Levis A; Fiedler W; Cerqui E; Breccia M; Fioritoni G; Salih HR; Cazzola M; Melillo L; Carella AM; Brandts CH; Morra E; von Lilienfeld-Toal M; Hertenstein B; Wattad M; Lübbert M; Hänel M; Schmitz N; Link H; Kropp MG; Rambaldi A; La Nasa G; Luppi M; Ciceri F; Finizio O; Venditti A; Fabbiano F; Döhner K; Sauer M; Ganser A; Amadori S; Mandelli F; Döhner H; Ehninger G; Schlenk RF; Platzbecker U; ; ;
    N Engl J Med; 2013 Jul; 369(2):111-21. PubMed ID: 23841729
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Retinoic acid syndrome induced by arsenic trioxide in treating recurrent all-trans retinoic acid resistant acute promyelocytic leukemia.
    Che-Pin Lin ; Huang MJ; Chang IY; Lin WY; Sheu YT
    Leuk Lymphoma; 2000 Jun; 38(1-2):195-8. PubMed ID: 10811463
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Superiority of an arsenic trioxide-based regimen over a historic control combining all-trans retinoic acid plus intensive chemotherapy in the treatment of relapsed acute promyelocytic leukemia.
    Thomas X; Pigneux A; Raffoux E; Huguet F; Caillot D; Fenaux P
    Haematologica; 2006 Jul; 91(7):996-7. PubMed ID: 16757416
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The pharmacokinetics of therapeutic arsenic trioxide in acute promyelocytic leukemia patients.
    Ghiuzeli CM; Stýblo M; Saunders J; Calabro A; Budman D; Allen S; Devoe C; Dhingra R
    Leuk Lymphoma; 2022 Mar; 63(3):653-663. PubMed ID: 34689693
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Arsenic trioxide may improve the prognosis of APL with ider(17)(q10): report of a rare adult case of acute promyelocytic leukemia with ider(17)(q10)t(15;17) showing poor response to all-trans retinoic acid.
    Tong H; Li K; Mei C; Wang H; Chen Z; Jin J
    Ann Hematol; 2011 Dec; 90(12):1493-4. PubMed ID: 21431323
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.